Reduced Glucose Variability Is Associated With Improved Quality of Glycemic Control in Patients With Type 2 Diabetes: A 12-Month Observational Study

Klaus-Dieter Kohnert, Peter Heinke, Lutz Vogt, Eckhard Zander, Gert Fritzsch, Petra Augstein, Eckhard Salzieder

Abstract

Background: Current diabetes management relies mainly on hemoglobin A1C measurement to assess quality of treatment and to adjust therapy. We assessed the long-term effectivity of therapeutic adjustments in type 2 diabetes with specific focus on indices of glucose variability and multiple criteria for quality of glycemic control.

Methods: Continuous glucose monitoring data collected during an observational study involving 405 outpatients with type 2 diabetes were analyzed at baseline and after 12 months. We evaluated the following criteria for glucose variability and quality of glycemic control: mean amplitude of glycemic excursions (MAGE), SD around the mean sensor glucose, mean of daily differences (MODD), fasting and mean sensor glucose, time outside specified glucose ranges, the Glycemic Risk Assessment Diabetes Equation (GRADE) score, High Blood Glucose Index (HBGI), and Low Blood Glucose Index (LBGI). Patients were classified according to quartiles of MAGE.

Results: Indices of glucose variability were reduced by 15 to 23% (P < 0.001 for all) during 12 months in the upper MAGE quartile (≥ 5.7 mmol/l). These reductions were associated with improvements in measures of glycemic control (P < 0.05), except for fasting sensor glucose (P = 0.23). Both time spent at < 3.9 mmol/l and at > 8.9 mmol/l decreased by 57% and 36% (P < 0.001 for both), respectively. MAGE and MODD correlated strongly with indices of glycemic control but weakly with A1C. The stepwise multiple regression analysis demonstrated that the mean amplitude of glycemic excursions and mean sensor glucose were the main determinants of time spent at < 3.9 mmol/l and at > 8.9 mmol/l (R² = 0.374 and 0.877, P < 0.001 for both).

Conclusions: Reduction of elevated glucose variability in type 2 diabetic outpatients is associated with lower risk of hypo- and hyperglycemia, and lower A1C values.

Keywords: Type 2 diabetes mellitus; Indices of glucose variability; Quality measures of glycemic control; Continuous glucose monitoring; Observational study

Introduction

Since evidence from large clinical trials has linked A1C to vascular complications of diabetes [1, 2] current glycemic management relies mainly on A1C measurements. Main determinants of A1C in patients with type 2 diabetes are both fasting hyperglycemia and postprandial glucose excursions but their relative contribution to the overall diurnal hyperglycemia varies with the quality of diabetes control [3]. Increased cardiovascular risk in type 2 diabetes is only partly explained by traditional cardiovascular risk factors. Chronic sustained hyperglycemia increases the risk, and postprandial hyperglycemia has been associated with cardiovascular risk independent of A1C or fasting glycemia [4, 5], even if a recent study has failed to show any difference in postprandial vs. basal glycemia strategy for future cardiovascular events [6]. However, neither of these studies addressed the role of glucose variability, but instead considered the importance of chronic sustained hyperglycemia.

In the majority of studies so far performed in patients with type 1 diabetes, short-term glucose fluctuations have been found to have little impact on the development of diabetic vascular disease [7]. However, there are some indications from type 2 diabetes studies that increased glucose variability could be an A1C-independent predictor for diabetes complications and mortality [8]. For example, increased glucose variability obviously accelerates atherogenesis [9, 10] and appears to be one of the risk factors for microalbuminuria.
Physicians could use the Karlsburg Diabetes Management System (KADIS®) for assistance in the adjustment of antihyperglycemic therapy according to the guidelines of the German Diabetes Association and the consensus algorithm for the medical management of type 2 diabetes. The patients had been seen by their physicians at least quarterly for glycemic control and measurements of A1C. All study participants had provided witnessed, written informed consent before participation.

Patient characteristics
Of the 448 patients with type 2 diabetes, fulfilling the enrollment criteria, 405 patients had complete data on glycemic control, including data from two 3-day CGM measurement periods 12 months apart, and were retrospectively evaluated in the present observational study. The 405 enrolled patients were Caucasians, and 278 (68.6%) were men. Patients were 65.9 ± 8.7 (mean ± SD) years old, with a known disease duration of 12.0 ± 8.9 years, and their body mass index was 11.9 ± 3.2 BU (bread exchange units/day); BMI was 30.9 ± 5.3. Antihyperglycemic treatment consisted of diet alone in 42 (10.3%) and OHAs in 131 (32.3%), either sulfonylurea, metformin or pioglitazone alone or combinations thereof; 105 (25.9%) received insulin in combination with OHAs and 147 (36.3%) insulin alone.

Study procedures
At baseline and after 12 months, a CGM sensor (Medtronic MiniMed, Northridge, CA) was inserted under ambulatory conditions, calibrated according to the standard Medtronic MiniMed operating guidelines, and CGM was performed for 68.4 ± 6.1 h (mean ± SD) and 68.9 ± 5.5 h, respectively. Patients used their home blood glucose monitors, entered at least 4 blood glucose meter readings per day into the CGM monitor for calibration, recorded logbook entries of particular event (intake of hypoglycemics, insulin doses injected, food intake, physical exercise, hypoglycemia symptoms, and other matters potentially affecting glucose control). Patients and the health care team were blinded to the glucose results until download after the testing period.

CGM data were downloaded using MiniMed Solution Software (Medtronic MiniMed). CGM profiles with less than 4 blood glucose meter entries or incomplete monitoring periods were discarded.

Measures of glucose variability
Using the CGM datasets, the following measures of within-day glucose variability were calculated: the mean amplitude of glycemic excursions (MAGE) and the overall SD around the sensor glucose; the latter was calculated for each day and then averaged over the 3-day CGM period. The mean of daily differences (MODD) was used as a measure of...
between-day glycemic variability and calculated as the mean of the absolute difference of glucose values from two consecutive days [23].

**Measures of quality of glycemic control**

These measures included fasting sensor glucose (FSG) and mean sensor glucose (Mean SG), time spent at > 8.9 mmol/l, time spent at < 3.9 mmol/l, the Low Blood Glucose Index (LBGI) and High Blood Glucose Index (HBGI) [24], and the Glycemic Risk Assessment Diabetes Equation (GRADE)
score [25]. All parameters were calculated for each day and then averaged over the 3-day CGM period. A1C was analyzed in certified clinical laboratories using ion-exchange high-performance liquid chromatography (normal range 4.6 - 6.0\%).

### Statistical analysis

Data are presented as means ± SD or medians (25th - 75th percentile). Hyperglycemia: > 8.9 mmol/l; target range: 3.9 - 8.9 mmol/l; hypoglycemia: < 3.9 mmol/l.

### Results

#### Analyses by baseline mean amplitude of glycemic excursions

Patients were classified by quartiles of baseline values of the mean amplitude of glycemic excursions as follows: < 3.0, 3.0 - < 4.3, 4.3 - < 5.7, and ≥ 5.7 mmol/l. The gender distribution between the quartiles was not different (P = 0.13),...
Table 2. Changes From Baseline in Measures of Glucose Variability and Glycemic Control by Quartiles of the Mean Amplitude of Glycemic Excursions (MAGE)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>1st (n = 94)</th>
<th>2nd (n = 105)</th>
<th>3rd (n = 100)</th>
<th>4th (n = 106)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glucose variability</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔMAGE (mmol/l)</td>
<td>0.75 ± 1.37‡</td>
<td>0.31 ± 1.45*</td>
<td>-0.21 ± 1.77</td>
<td>-1.78 ± 2.29‡</td>
</tr>
<tr>
<td>ΔSD (mmol/l)</td>
<td>0.25 ± 0.48‡</td>
<td>0.10 ± 0.54</td>
<td>-0.05 ± 0.59</td>
<td>-0.61 ± 0.83‡</td>
</tr>
<tr>
<td>ΔMODD (mmol/l)</td>
<td>0.23 ± 0.54‡</td>
<td>0.13 ± 0.70</td>
<td>-0.02 ± 0.76</td>
<td>-0.42 ± 1.10‡</td>
</tr>
<tr>
<td><strong>Glycemic control</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔA1C (%)</td>
<td>-0.15 ± 0.57*</td>
<td>-0.02 ± 0.86</td>
<td>-0.10 ± 0.86</td>
<td>-0.32 ± 0.82‡</td>
</tr>
<tr>
<td>(mmol/l)</td>
<td>-1.65 ± 6.27</td>
<td>-0.25 ± 9.35</td>
<td>-1.14 ± 9.35</td>
<td>-3.49 ± 9.00</td>
</tr>
<tr>
<td>ΔFasting glucose (mmol/l)</td>
<td>0.14 ± 1.18</td>
<td>-0.05 ± 1.81</td>
<td>0.02 ± 1.81</td>
<td>-0.30 ± 2.50</td>
</tr>
<tr>
<td>ΔMean glucose (mmol/l)</td>
<td>0.14 ± 1.00</td>
<td>-0.02 ± 1.54</td>
<td>-0.17 ± 1.79</td>
<td>-0.58 ± 1.81†</td>
</tr>
<tr>
<td>ΔHyperglycemia (h/day)</td>
<td>0.4 (-0.7 - 2.3)*</td>
<td>-0.2 (-2.0 - 1.4)</td>
<td>-0.6 (-3.0 - 2.5)</td>
<td>-1.4 (-4.2 - 1.3)†</td>
</tr>
<tr>
<td>ΔTarget range (h/day)</td>
<td>-0.5 (-2.5 - 0.7)*</td>
<td>0.6 (-1.7 - 2.7)</td>
<td>0.2 (-2.5 - 3.2)</td>
<td>2.2 (-0.2 - 5.5)‡</td>
</tr>
<tr>
<td>ΔHypoglycemia (min/day)</td>
<td>0.0 (-7.1 - 5.3)</td>
<td>0.0 (-30.3 - 25.8)</td>
<td>0.0 (-26.1 - 15.0)</td>
<td>-5.1 (-94.4 - 21.9)†</td>
</tr>
<tr>
<td>ΔGRADE score</td>
<td>0.54 ± 2.18*</td>
<td>-0.11 ± 3.44</td>
<td>-0.47 ± 3.99</td>
<td>-1.80 ± 3.73‡</td>
</tr>
<tr>
<td>ΔHBGI</td>
<td>0.1 (-0.1 - 0.7)†</td>
<td>-0.0 (-0.6 - 0.7)</td>
<td>-0.2 (-0.9 - 0.8)</td>
<td>-0.8 (-2.4 - 0.3)‡</td>
</tr>
<tr>
<td>ΔLBGI</td>
<td>0.0 (-0.2 - 0.2)</td>
<td>0.0 (-0.3 - 0.2)</td>
<td>-0.0 (-0.2 - 0.3)</td>
<td>-0.1 (-0.8 - 0.2)*</td>
</tr>
</tbody>
</table>

Data are presented as means ± SD or medians (25th - 75th percentile) of differences (Δ) from baseline. Negative values correspond to a reduction in parameters. P values for paired t test or Wilcoxon signed-rank test within individual patients are shown: *P < 0.05; †P < 0.01; ‡P < 0.001. Hyperglycemia: > 8.9 mmol/l; target range: 3.9 - 8.9 mmol/l; hypoglycemia: < 3.9 mmol/l. Significance level P < 0.05.

Table 3. Correlation Matrix for the Mean Amplitude of Glycemic Excursions (MAGE) and Measures of Glycemic Control: GRADE Score and A1C

<table>
<thead>
<tr>
<th></th>
<th>MAGE_{BL}</th>
<th>MAGE_{BL-EP}</th>
<th>GRADE_{BL}</th>
<th>GRADE_{BL-EP}</th>
<th>A1C_{BL}</th>
</tr>
</thead>
<tbody>
<tr>
<td>ΔMAGE_{BL-EP}</td>
<td>-0.540‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRADE_{BL}</td>
<td>0.530‡</td>
<td>-0.167‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔGRADE_{BL-EP}</td>
<td>-0.256‡</td>
<td>0.371‡</td>
<td>-0.619‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A1C_{BL}</td>
<td>0.328‡</td>
<td>-0.076</td>
<td>0.531‡</td>
<td>-0.203‡</td>
<td></td>
</tr>
<tr>
<td>ΔA1C_{BL-EP}</td>
<td>-0.081</td>
<td>0.103*</td>
<td>-0.247‡</td>
<td>0.321‡</td>
<td>-0.579‡</td>
</tr>
</tbody>
</table>

Data represent Pearson correlation coefficients. The area above the diagonal is not shown because the table is symmetrical. *P < 0.05 (two-sided); †P < 0.01 (two-sided). GRADE: Glycemic Risk Association Diabetes Equation; BL: baseline; EP: endpoint. ΔBL-EP: difference between baseline and endpoint of the 12-month observation period.
known diabetes duration was longer (P < 0.001), and A1C values were significantly higher in the top quartile compared with the lower quartiles (P < 0.001). Carbohydrate intake and characteristics, such as age and BMI, did not significantly vary between the quartiles. Antihyperglycemic therapy was different (P < 0.001) as well as the proportion of patients receiving antihypertensive treatment (P = 0.004). Figure 1 illustrates the proportions of the various classes of antihyperglycemic medication at baseline (Fig. 1A) and at 12 months (Fig. 1B). It can be seen, that the proportion of patients receiving insulin either alone or as add-on to OHA therapy was highest in the 4th quartile and had increased from 75% up to 83%. The proportion of patients treated with OHAs decreased from quartile 1 to 4 but did not markedly change during the study.

Glucose variability and quality of glycemic control

To evaluate changes in glycemic control, we computed 3 relevant measures of glucose variability and 9 measures of quality of glycemic control from the CGM datasets. Table 1 shows the corresponding baseline values for the quartiles of the mean amplitude of glycemic excursions.

The changes that occurred from baseline during the 12-month observation period are summarized in Table 2. Significant reductions in glucose variability were observed in the 4th quartile.

The percentage reductions achieved in the mean amplitude of glycemic excursions, SD around the mean sensor glucose, and the mean of daily differences were -23%, -22%, and -15%, respectively. In contrast, the two lower quartiles showed even moderate increases, which were statistically significant in the 1st quartile for all indices of glucose variability, but in the 2nd quartile only for the mean amplitude of glycemic excursions. The small reductions observed in the 3rd quartile were not statistically significant. Table 2 also shows that 8 of the 9 criteria of quality of glycemic control, including A1C, were significantly improved in the top quartile of the mean amplitude of glycemic excursions. Compared with the baseline values, the time spent at glucose levels < 3.9 mmol/l was reduced by a median value of 5.1 min/day (-57%) and time spent at > 8.9 mmol/l by 1.4 h/day (-36%). Correspondingly, the time spent within the glucose target range 3.9 - 8.9 mmol/l was increased by 2.2
The results of the stepwise forward regression analyses provided in Table 4 show that mean sensor glucose and the mean amplitude of glycemic excursions were the main predictors of the dependent variables time spent at < 3.9 mmol/l and time spent at > 8.9 mmol/l, explaining 37.4% and 87.7%, respectively, of the variance in these measures of glycemia.

The independent variables such as A1C, BMI, diabetes duration, antidiabetic or antihypertensive therapy, carbohydrate consumption (bread exchange units), age, gender, and the physicians’ specialty (diabetes specialist/general practitioner) failed to enter these regression models.

**Relationships among the mean amplitude of glycemic excursions, measures of quality of glycemic control, and changes from baseline**

Using linear regression analysis, we identified a number of significant relationships between baseline measures of glucose variability and baseline measures of short- and long-term quality of glycemic control. The relationships among the mean amplitude of glycemic excursions (MAGE), the Glycemic Risk Assessment Diabetes Equation (GRADE) score, A1C, and their changes from baseline (Δ) are demonstrated in Table 3.

The mean amplitude of glycemic excursions correlated well with the Glycemic Risk Assessment Diabetes Equation score (r = 0.530) and weakly with A1C (r = 0.328). Changes in the mean amplitude of glycemic excursions between baseline and at 12 months (ΔMAGEBL-EP) did not correlate with A1C (r = -0.076), were negatively correlated with the Glycemic Risk Assessment Diabetes Equation score (r = -0.167), and weakly positive with ΔGRADEBL-EP and ΔA1CBL-EP (r = 0.371 and r = 0.103, respectively). Hyperglycemia, measured as time spent at > 8.9 mmol/l and the High Blood Glucose Index (HBGI), correlated moderately with the mean amplitude of glycemic excursions (r = 0.483 and 0.465, P < 0.001 for both) and strongly with the Glycemic Risk Assessment Diabetes Equation score (r = 0.929 and 0.964, P < 0.001 for both). Measures of hypoglycemia, such as time spent at < 3.3 mmol/l and the Low Blood Glucose Index (LBGI) correlated weakly with the mean amplitude of glycemic excursions and the mean of daily differences (P < 0.001) but not with the Glycemic Risk Assessment Diabetes Equation score (P > 0.05) (data not shown). When the relationship between the mean amplitude of glycemic excursions and mean sensor glucose levels achieved at 12 month was analyzed, the correlation coefficient was as low as 0.452, and a rather wide range of glucose variability values at the same mean sensor glucose levels could be observed (Fig. 2).

**Multivariate regression analysis with hypo- and hyperglycemia as the dependent variables**

The results of the stepwise forward regression analyses

Discussion

In this study, we used several criteria recently proposed [16] to evaluate glucose variability and quality of glycemic control in a cohort of outpatients with type 2 diabetes, receiving various antihyperglycemic treatments. The important finding of our study is that a distinct reduction of glucose variability was closely associated with consistent improvements of characteristic measures of glycemic control in a segment of patients with increased glycemic excursions. This observation is in keeping with findings of a short-term study, which included a heterogeneous group of patients (80.2% had type 1 diabetes and 19.8% type 2 diabetes) on intensified insulin therapy, using real-time CGM [17, 26]. As the results of our retrospective analysis clearly demonstrate, improvements in indices of glucose variability and quality of glycemic control achieved in those patients with elevated glycemic excursions and less-well controlled glycemia (mean baseline A1C 7.5%) were accompanied by a respectively small 4.3% and 6.7% relative decrease in A1C and mean glucose levels, while fasting glucose was not significantly changed. By contrast, the percentage reduction found for the glucose variability was roughly 3 - 4 fold greater. In agreement with results from the ADAG Study [27], the mean amplitude of glycemic excursions was moderately or weakly correlated with measures of general glycemia such as mean sensor glucose and A1C, indicating that patients at the same mean glucose or A1C level, even if in the target range, can have greatly different values of glucose variability.

Reduced glucose variability was further associated with decreased time spent at < 3.9 mmol/l and at > 8.9 mmol/l. Indeed, patients in the top quartile of the mean amplitude of glycemic excursions experienced as much as 2.2 h/day net increase in time spent within the 3.9 - 8.9 mmol/l glycemic target range. This suggests that minimizing glucose variability allows tighter long-term glycemic control, i.e., lowering of A1C, without increasing the risk of hypo- and hyperglycemia. We found that the mean amplitude of glycemic excursions (MAGE) was a significant predictor of both hypo- and hyperglycemia, whereas A1C and other factors such as diabetes duration, carbohydrate intake, and antihyperglycemic therapy failed to enter the multivariate regression models.
As we have previously shown, the failing postprandial β-cell dysfunction is one of the most important factors responsible for increased glucose variability [28]. It was the purpose of this study to evaluate associations of glucose variability with various quality indices of glycemic control rather than to assess the influence of factors such as the glycemic index of consumed food, specific dose escalation or medication compliance.

Weaknesses of the current study are its observational nature and the absence of repeated CGMs in-between. However, it was our purpose to assess the outcomes 12 months after therapeutic adjustments, as in daily clinical practice, outpatients with type 2 diabetes can hardly be encouraged to run CGM in shorter intervals as long as they see their A1C values staying around the target range or even improve. Since A1C levels were decreasing over the entire study cohort during the observation period, there was a clear trend for overall glycemic improvement. This substantiates our conclusions that glucose variability is associated with short- and long-term measures of glycemic control. The strengths of the study include evaluation of glycemic control in a representative cohort of patients with type 2 diabetes from a great number of centers and cared for by primary care physicians in day-to-day management of diabetes. Furthermore, CGM measurements were performed blinded which inspired patients to evaluate their glucose profiles after download together with the attending physicians and to help gain more insight into diabetes control.

In summary, we evaluated retrospectively an observational study that used CGM to adjust antihyperglycemic therapy and assess the effectiveness of long-term diabetes control. Our data suggest that indices of glucose variability and of quality of glycemic control, provided through the use of CGM, enable the attending physician to achieve individual glycemic targets without increasing the risk of hypo- and hyperglycemia. Treatment decisions made using the indices evaluated in the present study could be more successful in improving glycemia than those based only on quarterly A1C testing. Especially in those patients with increased glucose excursions, minimizing glucose variability may help achieve better glycemic control and prevent long-term diabetes complications.

**Conflict of Interest**

No potential conflicts of interest relevant to this article were reported.

**References**

13. Kilpatrick ES. Arguments for and against the role of glucose variability in the development of diabetes compli-
Glucose Variability and Glycemic Control in Type 2 Diabetes